BrainsWay (BWAY) vs Treace Medical Concepts (TMCI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Treace Medical Concepts (TMCI) has outperformed BrainsWay (BWAY) over the past year, gaining 50.7% versus a gain of 13.9%. Over five years, BWAY leads with a +130.7% price change compared with -75.9% for TMCI. BrainsWay is the larger company by market cap ($341.3 million vs $282.6 million), about 1.2 times the size.
BrainsWay converts more of its revenue into profit, with a net margin of 7.1% versus -27.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BWAY | TMCI |
|---|---|---|
| Share price | $8.48 | $4.31 |
| Market cap | $341.35M | $282.56M |
| 1-day change | -2.86% | -0.92% |
| YTD return | -10.83% | +75.92% |
| 1-year return | +13.90% | +50.70% |
| 5-year return | +130.75% | -75.91% |
| P/E ratio (TTM) | 35.33 | — |
| Forward P/E | 16.96 | — |
| EPS (TTM) | $0.24 | $-0.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.02M | $212.69M |
| Revenue growth (YoY) | +29.04% | +1.59% |
| Net income (latest FY) | $2.92M | $-59.00M |
| Gross margin | 74.56% | 79.81% |
| Operating margin | 3.39% | -25.46% |
| Net margin | 7.12% | -27.74% |
| 52-week high | $17.40 | $5.44 |
| 52-week low | $7.30 | $1.17 |
| Distance from 52-week high | -51.26% | -20.77% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +127.24% | +43.16% |
| Average volume | 110.35K | 267.11K |
| Shares outstanding | 40.25M | 65.56M |
| Employees | 129 | 450 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TMCI has outperformed BWAY by 36.8 percentage points over the past year.
- BrainsWay is more profitable, keeping 7.1 cents of every revenue dollar as net income versus -27.7 cents for Treace Medical Concepts.
- BrainsWay grew revenue faster in its latest fiscal year (+29.04% vs +1.59%).
About BrainsWay
BWAY stock →BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 129 employees
About Treace Medical Concepts
TMCI stock →Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions.
Health Care · Medical/Dental Instruments · 450 employees
BWAY vs TMCI FAQ
Which is bigger, BrainsWay or Treace Medical Concepts?
BrainsWay (BWAY) is larger, with a market capitalization of $341.35M compared with $282.56M for Treace Medical Concepts (TMCI).
Which stock has performed better over the past year, BWAY or TMCI?
TMCI returned +50.70% over the past 12 months, compared with +13.90% for BWAY (price return, excluding dividends). Past performance does not predict future results.
Are BrainsWay and Treace Medical Concepts in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.